KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
97 hedge funds and large institutions have $314M invested in KalVista Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 23 closing their positions.
19% more call options, than puts
Call options by funds: $164K | Put options by funds: $138K
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
1.53% more ownership
Funds ownership: 95.67% → 97.2% (+1.5%)
8% less funds holding
Funds holding: 105 → 97 (-8)
23% less capital invested
Capital invested by funds: $408M → $314M (-$93.8M)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$18.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.56M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$5.57M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.03M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$19.9M |
| 2 |
DM
Deerfield Management
New York
|
-$15.7M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.39M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.31M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.79M |
KALV Hedge Fund Activity: Q4 2021 in Review
97 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2021, worth a combined $314M — down 23% from $408M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KALV and 16 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 32 added.
The largest buyer was Frazier Management, adding an estimated $18.3M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $19.9M sold.
- 97 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2021, down from 105 in Q3 2021.
- Funds reported $314M of KalVista Pharmaceuticals stock for Q4 2021, down 23% quarter-over-quarter.
- 16 funds opened new KalVista Pharmaceuticals positions in Q4 2021 and 23 closed out, a net change of -7 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2021 was Frazier Management, an estimated $18.3M added.
- The largest KalVista Pharmaceuticals seller in Q4 2021 was Janus Henderson Group, an estimated $19.9M sold.
Based on aggregated 13F filings for Q4 2021.